文献速递肝病

美国成年人群中VCTE测定的CAP和LSM是全因死亡的独立预测因子

CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population.
PubMed 文献 · Hepatology · 2023-01-03

该研究基于2017-2018年美国国家健康与营养调查(NHANES)中4192名≥18岁成年人,通过瞬时弹性成像(TE)测定受控衰减参数(CAP)和肝脏硬度值(LSM),随访至2019年12月31日。平均随访24.4个月期间共68例死亡(1.6%)。多因素Cox模型显示CAP和LSM均为全因死亡的独立预测因子,LSM≥13.6 kPa者死亡风险最高。

要点

  • CAP和LSM是普通美国成年人群全因死亡的独立预测因子。
  • LSM≥13.6 kPa者死亡风险最高,校正HR为3.2(95%CI 1.3-7.8)。
  • CAP≥285定义的NAFLD者死亡风险约为非NAFLD的2.2倍(95%CI 1.0-4.7)。

核心结论

  • 研究结果强调肝脏健康可作为普通人群全因死亡的预测指标。

研究设计与样本

  • 前瞻性美国队列研究,纳入2017-2018年NHANES中4192名≥18岁、TE测定的CAP和LSM数据可靠的美国成年人。
  • 通过关联国家死亡索引记录至2019年12月31日确定全因死亡和死因别死亡。
  • 采用Cox模型估计HR和95%CI。

主要发现

  • 平均随访24.4个月期间共68例死亡(1.6%)。
  • CAP(校正HR 1.01,95%CI 1.0-1.05)和LSM(校正HR 1.06,95%CI 1.02-1.11)与全因死亡独立相关。
  • CAP≥285定义的NAFLD者死亡风险约为非NAFLD者的2.2倍(95%CI 1.0-4.7)。
  • LSM 9.7-13.5(进展期纤维化)和LSM≥13.6(肝硬化)者累积死亡率显著高于LSM<9.7者,组间趋势P值<0.01。
  • LSM≥13.6者死亡风险最高(校正HR 3.2,95%CI 1.3-7.8);与LSM<10(无进展期慢性肝病)相比,LSM 10-19.9(可能ACLD)和≥20 kPa(可能ACLD伴临床显著门脉高压)的死亡风险分别增加3.4倍(95%CI 1.0-13.8)和5.2倍(95%CI 1.2-22.3)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: Data retrospective cohort studies have shown that liver stiffness measurement (LSM) by transient elastography (TE, FibroScan) can predict mortality in patients with NAFLD, however, its ability to predict mortality at a population level is unknown. We investigated the ability of LSM and controlled-attenuation parameter (CAP) by TE to predict mortality in a prospective US cohort. APPROACH AND RESULTS: A total of 4192 US adults aged ≥18 years enrolled in the National Health, and Nutrition Examination Survey (NHANES) (2017-2018) with reliable information on CAP and LSM by TE were included in this analysis. All-specific and cause-specific mortality were ascertained by linkage to National Death Index records through December 31, 2019. Cox models were used to estimate HR and 95% CI. During a mean follow-up of 24.4 months, there were 68 deaths (1.6%). CAP (adjusted HR: 1.01, 95% CI: 1.0-1.05), and LSM (adjusted HR: 1.06, 95% CI: 1.02-1.11) were independently associated with overall mortality. NAFLD by CAP ≥285 had a 2.2-fold (95% CI: 1.0-4.7) increased odds of mortality compared with non-NAFLD. Cumulative mortality rates were significantly higher in participants with LSM of 9.7-13.5 (advanced fibrosis) and LSM ≥13.6 (cirrhosis) as compared with LSM <9.7; p value for trend across groups <0.01. LSM ≥13.6 displayed the highest mortality risk (adjusted HR: 3.2, 95% CI: 1.3-7.8). Compared with LSM <10 [absence of advanced chronic liver disease (ACLD)], LSM 10-19.9 (likely ACLD), and ≥20 kPa (likely ACLD with clinically significant portal hypertension) conferred a 3.4-fold (95% CI: 1.0-13.8) and 5.2-fold (95% CI: 1.2-22.3) increase in hazards of mortality. CONCLUSIONS: Our study findings highlight the importance of liver health as a predictor of overall mortality at a population level.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population. Hepatology. 2023. PMID: 36626638. doi:10.1097/HEP.0000000000000023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。